Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases – Biotech Investments

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and

May 31, 2024

Seagen positions Tukysa combo as option for breast cancer patients with brain metastases

The combination of Seagen’s Tukysa and Roche’s Kadcyla cut the risk of disease progression or death by 36% in HER2-positive breast cancer patients with brain

December 7, 2023

7 Ways Document Management Platform Offers Full Automation

Sohail Malik, VP, Healthcare Solutions, Messagepoint, Inc. For Medicare Advantage Organizations (MAOs), the summer months have historically been defined by the high stakes, tight turnarounds

January 20, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.